Posting some interesting AccBio info here as the other Ag test agreement thread is a month old already...
22 Nov'20 - Ginkgo Bioworks Funds Expansion of Rapid Antigen Test Manufacturing with Access Bio in New Jersey
https://synbiobeta.com/ginkgo-bioworks-funds-expansion-of-rapid-antigen-test-manufacturing-with-access-bio-in-new-jersey/
- AccBio signed contract with Ginkgo to supply 10m Ag RDTs + receive additional capital to expand Ag RDT manufacturing (for an undisclosed contract conditions + amount but I believe this was secured via new convertible notes; see below)
20 Nov'20 - Accbio KRX disclosure for US$7m+ expenditure for "purchase of automated production equipment to expand production capacity of corona diagnostic kits"http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201120900057
18 Nov'20 - AccBio KRX disclosure for US$10m convertible bonds being issued (~414k shares based on mkt price)
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201118900080
Btw Ginkgo Bioworks is one of the world's largest privately held biotech companies (US$4.2b valuation)
https://en.wikipedia.org/wiki/Ginkgo_Bioworks
https://www.ginkgobioworks.com/
And Ginkgo plans to collaborate with AccBio on future RDTs that leverage Ginkgo's synthetic biology technology to improve antibodies
https://www.360dx.com/business-news/ginkgo-bioworks-collaborating-access-bio-covid-19-antigen-tests#.X7uic2gzaUk
And separately:
20 Nov'20 - AccBio KRX disclosure for US$4.2m worth Ag RDTs purchase order by their US distro (Intrivo Diagnostics)
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201120900049
Though none of this is directly relevant to AT1 or financially we gain anything (yet), I have a couple assumptions/hopeful thoughts:
- AT1's second largest partner is doing quite well + its further investing in Ag RDT manufacturing ability, which means zero supply problems if AT1's requires large orders for markets like India (hopefully, right?)
- it is a solid market potential indicator that these companies expect to continue providing Covid19 related testing for the foreseeable future; seeing the size of investment $ still being thrown at this
- AccBio has the existing manufacturing licence for Pascal devices; which we saw in a previous KRX disclosure seems to be connected to new AccBio HIV RDT; there is also a possibility of 'new' future tests/markets being developed using Ginkgo organism tech + AccBio test strips + AT1 devices.
- Forums
- ASX - By Stock
- AT1
- AT1 FY21 - General Discussion + FA
AT1 FY21 - General Discussion + FA, page-357
-
-
- There are more pages in this discussion • 2,077 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.3¢ |
Change
0.001(4.55%) |
Mkt cap ! $14.70M |
Open | High | Low | Value | Volume |
2.3¢ | 2.3¢ | 2.3¢ | $1.039K | 45.19K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 224074 | 2.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.4¢ | 165930 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 224074 | 0.022 |
2 | 266255 | 0.021 |
8 | 975507 | 0.020 |
3 | 132683 | 0.019 |
1 | 55553 | 0.018 |
Price($) | Vol. | No. |
---|---|---|
0.024 | 165930 | 3 |
0.025 | 384755 | 4 |
0.026 | 390045 | 2 |
0.027 | 398550 | 2 |
0.028 | 100000 | 1 |
Last trade - 11.58am 09/08/2024 (20 minute delay) ? |
Featured News
AT1 (ASX) Chart |